Cellectar Biosciences, Inc.: directors' dealings · United States · SEC (Form 4)

About Cellectar Biosciences, Inc.

Cellectar Biosciences, Inc. (ticker: CLRB) is a U.S.-based biopharmaceutical company listed on the NASDAQ market in the United States. Its headquarters are in Florham Park, New Jersey. For investors, this is a classic small-cap clinical biotech story: valuation is driven primarily by pipeline execution, clinical readouts, regulatory milestones, and financing capacity rather than by a broad portfolio of marketed products. The company’s identity is built around its proprietary Phospholipid Drug Conjugate (PDC) platform, which is designed to selectively deliver therapeutic payloads to cancer cells while reducing off-target exposure. That platform is central to its competitive thesis. Cellectar describes itself as a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of proprietary cancer therapies, both independently and through research and development collaborations. Cellectar’s lead program is iopofosine I 131, a PDC designed to deliver iodine-131 in a targeted manner. The company states that this asset has received Breakthrough Therapy Designation from the FDA, which can enhance the program’s visibility and development momentum, although it does not guarantee approval. The pipeline also includes CLR 121225, an actinium-225-based program being developed for several solid tumors with significant unmet medical need, alongside preclinical PDC chemotherapeutic programs and partnered assets. In other words, the company remains highly pipeline-dependent, which is typical for a biotech at this stage. From a competitive standpoint, Cellectar operates in a crowded oncology landscape that includes large pharmaceutical companies, specialty biotechs, and an expanding radiopharmaceutical ecosystem. Its potential advantage lies less in scale and more in scientific differentiation: a targeted delivery technology that aims to improve efficacy and safety in difficult-to-treat cancers. The business footprint is predominantly U.S.-centered, with clinical and corporate activities anchored in the United States and broader partnering opportunities depending on the program. Recent corporate developments have also shaped the investment case. In June 2025, Cellectar announced a 1-for-30 reverse stock split, effective June 24, 2025, with the shares continuing to trade on the NASDAQ after the split. Such actions are often associated with maintaining exchange compliance and supporting share-price optics. The company was also notified in 2024 about a filing delay related to financial statement restatements, reflecting the operational and reporting risks that can accompany development-stage biotech names. More recently, SEC filings show new Form 4 insider transaction activity in May 2026, underscoring continued insider monitoring by market participants. Overall, CLRB should be viewed as a high-risk, event-driven oncology biotech with meaningful scientific optionality but substantial clinical and financing risk.